Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082968 | 1.00 | DRD2 (0.64) | DRD2DRD3 | |
| SCHEMBL13629877 | 0.92 | DRD2 (0.64) | DRD2DRD3 | |
| SCHEMBL3845261 | 0.92 | DRD2 (0.64) | DRD2DRD3 | |
| SCHEMBL13629983 | 0.87 | DRD2 (0.61) | DRD2DRD3 | |
| SCHEMBL5269048 | 0.87 | DRD2 (0.59) | DRD2DRD3 | |
| SCHEMBL4495784 | 0.87 | DRD2 (0.61) | DRD2DRD3 | |
| SCHEMBL13629915 | 0.86 | DRD2 (0.60) | DRD2DRD3 | |
| SCHEMBL4486979 | 0.86 | DRD2 (0.60) | DRD2DRD3 | |
| SCHEMBL13629935 | 0.86 | DRD2 (0.64) | DRD2DRD3 | |
| SCHEMBL4488629 | 0.86 | DRD2 (0.64) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1438302-B1 | NEW SULFONAMIDE DERIVATIVES AS D3-RECEPTOR LIGANDS | RICHTER GEDEON NYRT (HU) | 2012-05-30 | — | — | EP | disclosed |
| US-7473692-B2 | Sulfonamide derivatives as D3-receptor ligands | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-01-06 | — | — | US | disclosed |
| US-20050107397-A1 | Sulfonamide derivatives as d3-receptor agonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2005-05-19 | — | — | US | disclosed |
| EP-1438302-A1 | NEW SULFONAMIDE DERIVATIVES AS D3-RECEPTOR AGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003029233-A1 | NEW SULFONAMIDE DERIVATIVES AS D3-RECEPTOR AGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107397-A1 | Sulfonamide derivatives as d3-receptor agonists | SLC6A3, DRD3, GPR3 | DRD2 8/4885DRD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.